ENTA News and Press, Enanta Pharmaceuticals Inc. From 10/17/22

Enanta Pharmaceuticals, Inc . (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has dosed the first subject in its Phase 1 clinical trial of EDP-323, a novel, oral L-prote...

Enanta Pharmaceuticals ( NASDAQ: ENTA ) said it started a phase 2b trial of EDP-938 to treat adults with acute respiratory syncytial virus (RSV) infection who are at high risk of complications, including elderly and/or those with congestive heart failure, chronic obstructi...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the initiation of a Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the eff...

EDP-323 Demonstrates Potent Inhibition of RSV Replication and Associated Pathology 3D Airway Model Provides Accurate Insight into the Dynamics of RSV Infection Advances in hMPV Virology Methods Improve In Vitro Characterization of Direct-Acting Antivirals...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data related to its respiratory syncytial virus (RSV) program, as well as new v...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data for EDP-235, its lead oral coronavirus protease inhibitor specifically des...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor co...

Image source: The Motley Fool. Enanta Pharmaceuticals (NASDAQ: ENTA) Q3 2022 Earnings Call Aug 08, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Enanta Pharmaceuticals (ENTA) Q3 2022 Earnings Call Transcript

Enanta Pharmaceuticals, Inc. (ENTA) Q3 2022 Earnings Conference Call August 08, 2022, 16:30 ET Company Participants Jennifer Viera - Senior Director, IR & Corporate Communications Jay Luly - President, CEO & Director Paul Mellett - SVP, Finance & Admi...

Enanta Pharma press release ( NASDAQ: ENTA ): Q3 GAAP EPS of -$1.53 misses by $0.16 . Revenue of $19.48M (-9.8% Y/Y) misses by $1.25M . For further details see: Enanta Pharma GAAP EPS of -$1.53 misses by $0.16, revenue of $19.48M misses by $1.25M